BioNxt Solutions Advances MS Drug Studies

Bionxt Solutions Inc (TSE:BNXT) has released an update.

BioNxt Solutions Inc. is moving forward with its Cladribine program for treating multiple sclerosis, progressing to human comparative bioavailability studies in Europe. The company is also conducting a private placement of up to 6 million shares to raise approximately $1.62 million for further research and development. This funding will support their proprietary ODF Cladribine dosage form, aiming to tap into a global MS drug market projected to reach $41 billion by 2033.

For further insights into TSE:BNXT stock, check out TipRanks’ Stock Analysis page.